{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:11:10Z","timestamp":1791673870568,"version":"4.3.4"},"reference-count":102,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The clinical development of effective cancer immunotherapies, along with advances in genomic analysis, has led to the identification of tumor environmental features that predict for sensitivity to immune checkpoint blockade therapy (CBT). Early-phase clinical trial results have demonstrated the remarkable effectiveness of CBT in specific lymphoma subtypes, including classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Conversely, CBT has been relatively disappointing in follicular lymphoma and diffuse large B-cell lymphoma. These clinical observations, coupled with important scientific discoveries, have uncovered salient features of the lymphoma microenvironment that correlate with immunotherapy response in patients. For example, classical Hodgkin lymphoma is characterized by an inflammatory environment, genetic alterations that facilitate escape from immune attack, and sensitivity to PD-1 blockade therapy. On the other hand, for lymphomas in which measures of immune surveillance are lacking, including follicular lymphoma and most diffuse large B-cell lymphomas, anti-PD-1 therapy has been less effective. An improved understanding of the immune landscapes of these lymphomas is needed to define subsets that might benefit from CBT. In this article, we describe the immune environments associated with major B-cell lymphomas with an emphasis on the immune escape pathways orchestrated by these diseases. We also discuss how oncogenic alterations in lymphoma cells may affect the cellular composition of the immune environment and ultimately, vulnerability to CBT. Finally, we highlight key areas for future investigation, including the need for the development of biomarkers that predict for sensitivity to CBT in lymphoma patients.<\/jats:p>","DOI":"10.1182\/blood.2019000847","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T20:09:14Z","timestamp":1575317354000},"page":"523-533","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":159,"title":["The immune landscape and response to immune checkpoint blockade therapy in lymphoma"],"prefix":"10.1182","volume":"135","author":[{"given":"Justin","family":"Kline","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Godfrey","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2020022011594039100_B1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6230","key":"2020022011594039100_B2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"8","key":"2020022011594039100_B3","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2020022011594039100_B4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-67577-0_2","article-title":"Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment","volume":"1036","author":"Gajewski","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"1-2","key":"2020022011594039100_B5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"issue":"7528","key":"2020022011594039100_B6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2020022011594039100_B7","first-page":"984","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume-title":"Cell","author":"Jerby-Arnon","year":"2018"},{"issue":"2","key":"2020022011594039100_B8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"issue":"7559","key":"2020022011594039100_B9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"3","key":"2020022011594039100_B10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"issue":"9","key":"2020022011594039100_B11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-11-683003","article-title":"Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas","volume":"128","author":"Chong","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2020022011594039100_B12","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2020022011594039100_B13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2020022011594039100_B14","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020022011594039100_B15","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020022011594039100_B16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2020022011594039100_B17","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2020022011594039100_B18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2020022011594039100_B19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020022011594039100_B20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020022011594039100_B21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2020022011594039100_B22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020022011594039100_B23","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2020022011594039100_B24","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2020022011594039100_B25","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020022011594039100_B26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large b-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020022011594039100_B27","first-page":"812","article-title":"The immune landscape of cancer [published correction appears in Immunity. 2019;51(2):411-412]","volume-title":"Immunity.","author":"Thorsson","year":"2018"},{"issue":"8","key":"2020022011594039100_B28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"2020022011594039100_B29","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020022011594039100_B30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2020022011594039100_B31","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"7338","key":"2020022011594039100_B32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"6","key":"2020022011594039100_B33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"5","key":"2020022011594039100_B34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1292]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2020022011594039100_B35","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2004-12-4901","article-title":"NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes","volume":"106","author":"Feuerhake","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2020022011594039100_B36","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2020022011594039100_B37","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-16-1576","article-title":"The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma","volume":"23","author":"Keane","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"26","key":"2020022011594039100_B38","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2020022011594039100_B39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"29","key":"2020022011594039100_B40","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","article-title":"APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"2020022011594039100_B41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/2326-6066.CIR-17-0249","article-title":"Intratumoral CD8+ T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity","volume":"6","author":"Horton","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2020022011594039100_B42","first-page":"1120","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume-title":"Cell.","author":"Wei","year":"2017"},{"issue":"2","key":"2020022011594039100_B43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood.V59.2.226.226","article-title":"In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin\u2019s disease","volume":"59","author":"Poppema","year":"1982","journal-title":"Blood"},{"issue":"8","key":"2020022011594039100_B44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2020022011594039100_B45","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2020022011594039100_B46","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020022011594039100_B47","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2018-04-791566","article-title":"How I treat primary mediastinal B-cell lymphoma","volume":"132","author":"Giulino-Roth","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2020022011594039100_B48","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood.V87.4.1571.bloodjournal8741571","article-title":"Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene","volume":"87","author":"Joos","year":"1996","journal-title":"Blood"},{"issue":"1","key":"2020022011594039100_B49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","article-title":"Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival","volume":"108","author":"Roberts","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2020022011594039100_B50","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"200","key":"2020022011594039100_B51","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"issue":"127","key":"2020022011594039100_B52","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7607","key":"2020022011594039100_B53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"issue":"3","key":"2020022011594039100_B54","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res"},{"issue":"3","key":"2020022011594039100_B55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2020022011594039100_B56","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J"},{"issue":"11","key":"2020022011594039100_B57","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1158\/1078-0432.CCR-07-4709","article-title":"AP1-dependent galectin-1 expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features","volume":"14","author":"Rodig","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2020022011594039100_B58","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2020022011594039100_B59","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2020022011594039100_B60","first-page":"3149","article-title":"Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes","volume":"55","author":"Rivoltini","year":"1995","journal-title":"Cancer Res"},{"key":"2020022011594039100_B61","first-page":"1259","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume-title":"Cell","author":"McGranahan","year":"2017"},{"issue":"10","key":"2020022011594039100_B62","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V96.10.3569","article-title":"Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites","volume":"96","author":"Riemersma","year":"2000","journal-title":"Blood"},{"issue":"11","key":"2020022011594039100_B63","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2020022011594039100_B64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.exphem.2008.10.001","article-title":"Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL)","volume":"37","author":"Cycon","year":"2009","journal-title":"Exp Hematol"},{"issue":"2","key":"2020022011594039100_B65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2399","article-title":"Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways","volume":"216","author":"Booman","year":"2008","journal-title":"J Pathol"},{"issue":"1","key":"2020022011594039100_B66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"issue":"3","key":"2020022011594039100_B67","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.1027","article-title":"The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies","volume":"196","author":"Bingle","year":"2002","journal-title":"J Pathol"},{"issue":"5","key":"2020022011594039100_B68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2005.12.172","article-title":"Tumor-associated macrophages: the double-edged sword in cancer progression","volume":"23","author":"Chen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020022011594039100_B69","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2020022011594039100_B70","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"2020022011594039100_B71","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020022011594039100_B72","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s12032-011-0123-6","article-title":"High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma","volume":"29","author":"Cai","year":"2012","journal-title":"Med Oncol"},{"issue":"4","key":"2020022011594039100_B73","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/bloodadvances.2018020602","article-title":"PD-L1 and tumor-associated macrophages in de novo DLBCL","volume":"3","author":"McCord","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2020022011594039100_B74","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2014.113472","article-title":"Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial","volume":"100","author":"Riihij\u00e4rvi","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2020022011594039100_B75","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","article-title":"Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV","volume":"112","author":"Minard-Colin","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2020022011594039100_B76","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"6","key":"2020022011594039100_B77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2010.04.001","article-title":"Macrophages as mediators of tumor immunosurveillance","volume":"31","author":"Jaiswal","year":"2010","journal-title":"Trends Immunol"},{"issue":"5","key":"2020022011594039100_B78","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1083\/jcb.200708043","article-title":"Inhibition of \u201cself\u201d engulfment through deactivation of myosin-II at the phagocytic synapse between human cells","volume":"180","author":"Tsai","year":"2008","journal-title":"J Cell Biol"},{"issue":"5","key":"2020022011594039100_B79","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"18","key":"2020022011594039100_B80","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2020022011594039100_B81","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ni.2060","article-title":"Inflammation meets cancer, with NF-\u03baB as the matchmaker","volume":"12","author":"Ben-Neriah","year":"2011","journal-title":"Nat Immunol"},{"issue":"7092","key":"2020022011594039100_B82","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"issue":"7332","key":"2020022011594039100_B83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"7247","key":"2020022011594039100_B84","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"6","key":"2020022011594039100_B85","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI67250","article-title":"Lung tumor NF-\u03baB signaling promotes T cell-mediated immune surveillance","volume":"123","author":"Hopewell","year":"2013","journal-title":"J Clin Invest"},{"issue":"10","key":"2020022011594039100_B86","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood"},{"key":"2020022011594039100_B87","first-page":"481","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume-title":"Cell","author":"Reddy","year":"2017"},{"issue":"10","key":"2020022011594039100_B88","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"34","key":"2020022011594039100_B89","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020022011594039100_B90","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2020022011594039100_B91","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020022011594039100_B92","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"2020022011594039100_B93","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"2020022011594039100_B94","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"issue":"26","key":"2020022011594039100_B95","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020022011594039100_B96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"2020022011594039100_B97","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"17","key":"2020022011594039100_B98","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active idiotypic vaccination versus control immunotherapy for follicular lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020022011594039100_B99","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nm.4463","article-title":"Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms","volume":"24","author":"Bezzi","year":"2018","journal-title":"Nat Med"},{"issue":"7577","key":"2020022011594039100_B100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"issue":"6282","key":"2020022011594039100_B101","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"2020022011594039100_B102","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","article-title":"Myc cooperates with Ras by programming inflammation and immune suppression","volume":"171","author":"Kortlever","year":"2017","journal-title":"Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/8\/523\/1716665\/bloodbld2019000847.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/8\/523\/1716665\/bloodbld2019000847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T17:01:03Z","timestamp":1582218063000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/8\/523\/429214\/The-immune-landscape-and-response-to-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,2,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000847","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}